Industry news that matters to you.  Learn more

Archives for May 2014

NanoString Technologies Receives Canadian Market Approval for its Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

Metabolon Debuts New Client Portal at Bio-IT World Expo

Metabolon, Inc., a leader in metabolomics-driven biomarker discovery, recently announced the debut and impending launch of MetaboLync, the company’s innovative product offering which allows its clients to share, visualize, and explore metabolomics study results as a client directs. The company will unveil the capabilities of this new cloud-based software solution at the 2014 BIO-IT World Expo in Boston, Massachusetts on April 30th. Corey DeHaven, Metabolon’s VP of Information Systems, is the visionary architect of the company’s metabolomics data processing, analysis and storage systems. The company will exhibit, and Corey will provide, an introduction to the portal, including a demonstration of its capabilities, in an oral presentation within the Harnessing Data & Standards session.

New Versions of JMP Life Sciences Solutions Fuel Discoveries in Clinical Trials, Genomics Research

Risk-based monitoring methods new in JMP® Clinical software from SAS limit costly on-site audits of source data during clinical trials while protecting study participants. JMP Genomics now offers enhanced capabilities for analyzing data related to agriculture, pharmacogenomics, biotechnology and more.

KineMed Announces Participation in a Global, Multi-Company Effort to Advance and Standardize a Diabetic Research Model

KineMed, Inc. announced participation in a global, two year, multi-organization effort to advance and standardize a single mouse model of early diabetic disease detection and progression. The two year effort brings together cutting edge expertise and technology with a goal to produce a new mouse research model system that can streamline the research and development of advances in diabetic research and improve the clinical success of programs using the model.

New Prostate Cancer Blood Test Now Available in the US

Beckman Coulter Diagnostics, a global leader in prostate cancer diagnostics, announces national availability of the Prostate Health Index (phi)*, a simple, non-invasive blood test that is three times more specific in detecting prostate cancer1 than PSA (prostate-specific antigen). The new test’s accuracy decreases the need for many men who test positive for elevated PSA levels to undergo a biopsy in order to achieve a reliable diagnosis.